These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 36627880)

  • 21. Interpretation of the evidence for the efficacy and safety of statin therapy.
    Collins R; Reith C; Emberson J; Armitage J; Baigent C; Blackwell L; Blumenthal R; Danesh J; Smith GD; DeMets D; Evans S; Law M; MacMahon S; Martin S; Neal B; Poulter N; Preiss D; Ridker P; Roberts I; Rodgers A; Sandercock P; Schulz K; Sever P; Simes J; Smeeth L; Wald N; Yusuf S; Peto R
    Lancet; 2016 Nov; 388(10059):2532-2561. PubMed ID: 27616593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
    Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WMM; Vlachopoulos C; Wood DA; Zamorano JL; Cooney MT;
    Eur Heart J; 2016 Oct; 37(39):2999-3058. PubMed ID: 27567407
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
    Peng W; Qiang F; Peng W; Qian Z; Ke Z; Yi L; Jian Z; Chongrong Q
    Int J Cardiol; 2016 Nov; 222():119-129. PubMed ID: 27494723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
    Gouni-Berthold I; Descamps OS; Fraass U; Hartfield E; Allcott K; Dent R; März W
    Br J Clin Pharmacol; 2016 Dec; 82(6):1412-1443. PubMed ID: 27478094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unmet Needs in LDL-C Lowering: When Statins Won't Do!
    Krähenbühl S; Pavik-Mezzour I; von Eckardstein A
    Drugs; 2016 Aug; 76(12):1175-90. PubMed ID: 27456066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA; Lyon RA; Ling H
    Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
    Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
    Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.
    Sabatine MS; Giugliano RP; Keech A; Honarpour N; Wang H; Liu T; Wasserman SM; Scott R; Sever PS; Pedersen TR
    Am Heart J; 2016 Mar; 173():94-101. PubMed ID: 26920601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Retrospective Study to Examine Healthcare Costs Related to Cardiovascular Events in Individuals with Hyperlipidemia.
    Henk HJ; Paoli CJ; Gandra SR
    Adv Ther; 2015 Nov; 32(11):1104-16. PubMed ID: 26585336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-Risk Atherosclerotic Cardiovascular Disease in a Real-World Employed Japanese Population: Prevalence, Cardiovascular Event Rates, and Costs.
    Davis KL; Meyers J; Zhao Z; McCollam PL; Murakami M
    J Atheroscler Thromb; 2015; 22(12):1287-304. PubMed ID: 26289083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia.
    Punekar RS; Fox KM; Richhariya A; Fisher MD; Cziraky M; Gandra SR; Toth PP
    Clin Cardiol; 2015 Aug; 38(8):483-91. PubMed ID: 26100722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data.
    Hallberg S; Gandra SR; Fox KM; Mesterton J; Banefelt J; Johansson G; Levin LÅ; Sobocki P
    Eur J Health Econ; 2016 Jun; 17(5):591-601. PubMed ID: 26077550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
    Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
    N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
    Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
    N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
    Navarese EP; Kolodziejczak M; Schulze V; Gurbel PA; Tantry U; Lin Y; Brockmeyer M; Kandzari DE; Kubica JM; D'Agostino RB; Kubica J; Volpe M; Agewall S; Kereiakes DJ; Kelm M
    Ann Intern Med; 2015 Jul; 163(1):40-51. PubMed ID: 25915661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute and chronic impact of cardiovascular events on health state utilities.
    Matza LS; Stewart KD; Gandra SR; Delio PR; Fenster BE; Davies EW; Jordan JB; Lothgren M; Feeny DH
    BMC Health Serv Res; 2015 Apr; 15():173. PubMed ID: 25896804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A century of cholesterol and coronaries: from plaques to genes to statins.
    Goldstein JL; Brown MS
    Cell; 2015 Mar; 161(1):161-172. PubMed ID: 25815993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.
    Jernberg T; Hasvold P; Henriksson M; Hjelm H; Thuresson M; Janzon M
    Eur Heart J; 2015 May; 36(19):1163-70. PubMed ID: 25586123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
    Stone NJ; Robinson JG; Lichtenstein AH; Bairey Merz CN; Blum CB; Eckel RH; Goldberg AC; Gordon D; Levy D; Lloyd-Jones DM; McBride P; Schwartz JS; Shero ST; Smith SC; Watson K; Wilson PW; Eddleman KM; Jarrett NM; LaBresh K; Nevo L; Wnek J; Anderson JL; Halperin JL; Albert NM; Bozkurt B; Brindis RG; Curtis LH; DeMets D; Hochman JS; Kovacs RJ; Ohman EM; Pressler SJ; Sellke FW; Shen WK; Smith SC; Tomaselli GF;
    Circulation; 2014 Jun; 129(25 Suppl 2):S1-45. PubMed ID: 24222016
    [No Abstract]   [Full Text] [Related]  

  • 40. Principles of health economic evaluations of lipid-lowering strategies.
    Ara R; Basarir H; Ward SE
    Curr Opin Lipidol; 2012 Aug; 23(4):271-81. PubMed ID: 22617753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.